These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 2088196)

  • 21. Effect of culture media on the antifungal activity of miconazole and amphotericin B methyl ester.
    Hoeprich PD; Huston AC
    J Infect Dis; 1976 Oct; 134(4):336-41. PubMed ID: 789787
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans.
    Ernst EJ; Klepser ME; Pfaller MA
    Antimicrob Agents Chemother; 2000 Apr; 44(4):1108-11. PubMed ID: 10722525
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and toxicity evaluation of new amphotericin B micelle systems for brain fungal infections.
    Moreno-Rodríguez AC; Torrado-Durán S; Molero G; García-Rodríguez JJ; Torrado-Santiago S
    Int J Pharm; 2015 Oct; 494(1):17-22. PubMed ID: 26256151
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro activity of voriconazole and amphotericin B against Candida albicans, Candida krusei, and Cryptococcus neoformans in human cerebrospinal fluid.
    Al Jalali V; Sauermann R; Eberl S; Zeitlinger M
    Infection; 2019 Aug; 47(4):565-570. PubMed ID: 30725316
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative in vitro effects of liposomal amphotericin B, amphotericin B-deoxycholate, and free amphotericin B against fungal strains determined by using MIC and minimal lethal concentration susceptibility studies and time-kill curves.
    Ralph ED; Khazindar AM; Barber KR; Grant CW
    Antimicrob Agents Chemother; 1991 Jan; 35(1):188-91. PubMed ID: 2014976
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In-vitro activity of cilofungin (LY121019) in comparison with amphotericin B.
    Meunier F; Lambert C; Van der Auwera P
    J Antimicrob Chemother; 1989 Sep; 24(3):325-31. PubMed ID: 2681118
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hemolytic and antifungal activity of liposome-entrapped amphotericin B prepared by the precipitation method.
    Kim JC; Lee EO; Kim JY; Bae SK; Choi TB; Kim JD
    Pharm Dev Technol; 1997 Aug; 2(3):275-84. PubMed ID: 9552455
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Simpotentin, a new potentiator of amphotericin B activity against Candida albicans, produced by Simplicillium minatense FKI-4981.
    Uchida R; Kondo A; Yagi A; Nonaka K; Masuma R; Kobayashi K; Tomoda H
    J Antibiot (Tokyo); 2019 Mar; 72(3):134-140. PubMed ID: 30532035
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assay for yeast susceptibility to 5-fluorocytosine and amphotericin B in a frozen microtiter system.
    Ellis NS; Bartlett MS; Smith JW
    Am J Clin Pathol; 1979 Aug; 72(2):194-8. PubMed ID: 382827
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inactivation of amphotericin B by reducing agents: influences on growth inhibition of Candida albicans and lysis of erythrocytes.
    Weis MR; Levine HB
    Sabouraudia; 1972 Jul; 10(2):132-42. PubMed ID: 4557876
    [No Abstract]   [Full Text] [Related]  

  • 31. Lipoamino acid-based micelles as promising delivery vehicles for monomeric amphotericin B.
    Serafim C; Ferreira I; Rijo P; Pinheiro L; Faustino C; Calado A; Garcia-Rio L
    Int J Pharm; 2016 Jan; 497(1-2):23-35. PubMed ID: 26617315
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative susceptibility of four kinds of pathogenic fungi to amphotericin B and amphotericin B methyl ester.
    Huston AC; Hoeprich PD
    Antimicrob Agents Chemother; 1978 Jun; 13(6):905-9. PubMed ID: 354519
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New medium for in vitro susceptibility studies with amphotericin B.
    Utz CJ; White S; Shadomy S
    Antimicrob Agents Chemother; 1976 Oct; 10(4):776-7. PubMed ID: 791112
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synergistic antifungal activity and reduced toxicity of liposomal amphotericin B combined with gramicidin S or NF.
    Hopfer RL; Mehta R; Lopez-Berestein G
    Antimicrob Agents Chemother; 1987 Dec; 31(12):1978-81. PubMed ID: 2449867
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In-vivo therapeutic efficacy in experimental murine mycoses of a new formulation of deoxycholate-amphotericin B obtained by mild heating.
    Petit C; Chéron M; Joly V; Rodrigues JM; Bolard J; Gaboriau F
    J Antimicrob Chemother; 1998 Dec; 42(6):779-85. PubMed ID: 10052902
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reconstituted high density lipoprotein enriched with the polyene antibiotic amphotericin B.
    Oda MN; Hargreaves PL; Beckstead JA; Redmond KA; van Antwerpen R; Ryan RO
    J Lipid Res; 2006 Feb; 47(2):260-7. PubMed ID: 16314670
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Self-assembled amphotericin B-loaded polyglutamic acid nanoparticles: preparation, characterization and in vitro potential against Candida albicans.
    Zia Q; Khan AA; Swaleha Z; Owais M
    Int J Nanomedicine; 2015; 10():1769-90. PubMed ID: 25784804
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Toxicity of solubilized and colloidal amphotericin B formulations to human erythrocytes.
    Forster D; Washington C; Davis SS
    J Pharm Pharmacol; 1988 May; 40(5):325-8. PubMed ID: 2899626
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanisms of synergistic interactions between amphotericin B and flucytosine.
    Beggs WH
    J Antimicrob Chemother; 1986 Apr; 17(4):402-4. PubMed ID: 3519560
    [No Abstract]   [Full Text] [Related]  

  • 40. Biodegradable functional polycarbonate micelles for controlled release of amphotericin B.
    Wang Y; Ke X; Voo ZX; Yap SSL; Yang C; Gao S; Liu S; Venkataraman S; Obuobi SAO; Khara JS; Yang YY; Ee PLR
    Acta Biomater; 2016 Dec; 46():211-220. PubMed ID: 27686042
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.